Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 244113

Anti-IgE terapija astme i alergijskog rinitisa omalizumabom


Dodig, Slavica; Richter, Darko; Čepelak, Ivana; Benko, Bojan
Anti-IgE terapija astme i alergijskog rinitisa omalizumabom // Acta Pharmaceutica, 55 (2005), 123 - 138 (podatak o recenziji nije dostupan, pregledni rad, ostalo)


CROSBI ID: 244113 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Anti-IgE terapija astme i alergijskog rinitisa omalizumabom
(Anti-IgE therapy with omalizumab in asthma and allergic rhinitis)

Autori
Dodig, Slavica ; Richter, Darko ; Čepelak, Ivana ; Benko, Bojan

Izvornik
Acta Pharmaceutica (1330-0075) 55 (2005); 123 - 138

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, ostalo

Ključne riječi
astma; alergijski rinitis; terapija; anti-IgE; omalizumab
(asthma; allergic rhinitis; therapy; anti-IgE; omalizumab)

Sažetak
The pharmacology, efficacy, dosage, adverse events, and economics of anti IgE (omalizumab) are discussed. Omalizumab is generic name for the human/murine chimeric (recombinant humanized) monoclonal IgG antibody. Anti-IgE prevents IgE from attaching to effector cells, and thereby blunts IgE-mediated inflammatory responses. After subcutaneous administration it's absorption is slow, reaching peak concentration in serum after an average of 7-8 days. At recommended doses, serum free IgE levels decrease within 1 hour following the first dose and maintained between doses. Dose and dosing frequency is adjusted according to body mass and serum total IgE concentration before the start of treatment. Omalizumab administered subcutaneously is a effective treatment for add-on therapy in patients with poorly controlled, moderate-to-severe allergic asthma and allergic rhinitis (adults and adolescents >12 years). It reduce the requirement for inhaled corticosteroids while protecting against disease exacerbation. Omalizumab is well tolerated, but the safety profile required longer-term assessment in adults as well in children. The high cost limits its utility.

Izvorni jezik
Engleski

Znanstvena područja
Kemija, Kliničke medicinske znanosti, Farmacija



POVEZANOST RADA


Projekti:
0277001
0006631

Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Dječja bolnica Srebrnjak

Profili:

Avatar Url Slavica Dodig (autor)

Avatar Url Ivana Čepelak (autor)

Avatar Url Bojan Benko (autor)

Avatar Url Darko Richter (autor)

Poveznice na cjeloviti tekst rada:

Pristup cjelovitom tekstu rada

Citiraj ovu publikaciju:

Dodig, Slavica; Richter, Darko; Čepelak, Ivana; Benko, Bojan
Anti-IgE terapija astme i alergijskog rinitisa omalizumabom // Acta Pharmaceutica, 55 (2005), 123 - 138 (podatak o recenziji nije dostupan, pregledni rad, ostalo)
Dodig, S., Richter, D., Čepelak, I. & Benko, B. (2005) Anti-IgE terapija astme i alergijskog rinitisa omalizumabom. Acta Pharmaceutica, 55, 123 - 138.
@article{article, year = {2005}, pages = {123 - 138}, keywords = {astma, alergijski rinitis, terapija, anti-IgE, omalizumab}, journal = {Acta Pharmaceutica}, volume = {55}, issn = {1330-0075}, title = {Anti-IgE terapija astme i alergijskog rinitisa omalizumabom}, keyword = {astma, alergijski rinitis, terapija, anti-IgE, omalizumab} }
@article{article, year = {2005}, pages = {123 - 138}, keywords = {asthma, allergic rhinitis, therapy, anti-IgE, omalizumab}, journal = {Acta Pharmaceutica}, volume = {55}, issn = {1330-0075}, title = {Anti-IgE therapy with omalizumab in asthma and allergic rhinitis}, keyword = {asthma, allergic rhinitis, therapy, anti-IgE, omalizumab} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka::


  • Biological Abstracts
  • Chemical Abstracts
  • Excerpta Medica
  • Index Medicus





Contrast
Increase Font
Decrease Font
Dyslexic Font